Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy

(2018) Andrew J. Cowan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma

(2018) Ivana Moor et al.   BONE MARROW TRANSPLANTATION

Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease

(2018) Johannes M. Waldschmidt et al.   SEMINARS IN HEMATOLOGY

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

(2018) L. Sanoja-Flores et al.   Blood Cancer Journal

Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation

(2017) Rajshekhar Chakraborty et al.   HAEMATOLOGICA

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA

(2017) Anna Oberle et al.   HAEMATOLOGICA

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

(2017) Juan-Jose Lahuerta et al.   JOURNAL OF CLINICAL ONCOLOGY

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

(2017) J Flores-Montero et al.   LEUKEMIA

Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation

(2017) Rajshekhar Chakraborty et al.   HAEMATOLOGICA

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA

(2017) Anna Oberle et al.   HAEMATOLOGICA

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

(2016) B. Paiva et al.   BLOOD

Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay

(2016) Aaron Seth Rosenberg et al.   CLINICAL BIOCHEMISTRY

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era

(2016) R Chakraborty et al.   Blood Cancer Journal

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

(2014) J. Martinez-Lopez et al.   BLOOD

Quantification of clonal circulating plasma cells in relapsed multiple myeloma

(2014) Wilson I. Gonsalves et al.   BRITISH JOURNAL OF HAEMATOLOGY

Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma

(2013) Mark Korthals et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

Myeloma as a model for the process of metastasis: implications for therapy

(2012) I. M. Ghobrial   BLOOD

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

(2008) A Dispenzieri et al.   LEUKEMIA